BOOK
Clinical Management of Neuroendocrine Tumors of the Lung, An Issue of Thoracic Surgery Clinics, E-Book
(2014)
Additional Information
Book Details
Abstract
This issue of Thoracic Surgery Clinics is devoted to "Clinical Management of Neuroendocrine Tumors of the Lung" and is edited by Dr. Pier Luigi Filosso. Articles in this outstanding issue include: Pathology of neuroendocrine tumors, Clinical and radiological presentation of neuroendocrine tumors of the lung, Neuroendocrine tumors and endocrine syndromes, The significance of histology: typical and atypical bronchial carcinoids, Surgical management of well-differentiated lung neuroendocrine tumors, Surgical management of large cell neuroendocrine carcinoma (LCNC) of the lung, The role of surgery in small cell carcinoma, Management of thymic neuroendocrine tumors, Medical treatment of advanced thoracic neuroendocrine tumors, Radiometabolic treatment of advanced neuroendocrine tumors, Biological and clinical prognostic factors in thoracic neuroendocrine tumors, and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Clinical Management of Neuroendocrine Tumors\rof the Lung | i | ||
| Copyright | ii | ||
| Contributors | iii | ||
| Contents | v | ||
| Thoracic Surgery Clinics | viii | ||
| Preface | ix | ||
| A Historical Appreciation of Bronchopulmonary Neuroendocrine Neoplasia | 235 | ||
| Key points | 235 | ||
| From Gnosis to Sunesis | 235 | ||
| Early observations on lung tumors | 236 | ||
| Diagnosis of lung neuroendocrine tumors | 237 | ||
| Radiology | 237 | ||
| Bronchoscopy | 238 | ||
| Histopathology | 238 | ||
| Bronchial adenomas | 242 | ||
| Carcinoid tumors and the diffuse neuroendocrine system | 243 | ||
| Early recognition of a neuroendocrine cell genesis | 245 | ||
| The APUD concept and bronchial carcinoids | 245 | ||
| The role of immunohistochemistry in the delineation of bronchopulmonary NETs | 246 | ||
| Pulmonary neuroendocrine cells and neuroepithelial bodies | 247 | ||
| The continuum of bronchopulmonary neuroendocrine tumors | 248 | ||
| Peripheral carcinoids—a topographic concept | 248 | ||
| Bronchial carcinoids (typical) | 249 | ||
| Atypical bronchial carcinoid | 249 | ||
| Pulmonary neuroendocrine hyperplasia | 249 | ||
| Chemodectoma (paraganglioma) | 250 | ||
| Large-cell neuroendocrine carcinoma | 250 | ||
| Carcinoid, well-differentiated neuroendocrine carcinoma, intermediate neuroendocrine carcinoma, and small-cell neuroendocri ... | 250 | ||
| The classification conundrum | 250 | ||
| Summary | 252 | ||
| References | 252 | ||
| Pathology and Diagnosis of Neuroendocrine Tumors | 257 | ||
| Key points | 257 | ||
| Introduction: nature of the problem | 257 | ||
| Relevant anatomy and pathophysiology | 257 | ||
| Molecular Changes in Pulmonary Neuroendocrine Tumors | 257 | ||
| Diagnosis | 259 | ||
| Small Cell Carcinoma | 259 | ||
| Clinical features | 259 | ||
| Pathology | 259 | ||
| Large Cell Neuroendocrine Carcinoma | 261 | ||
| Pathology | 262 | ||
| Immunohistochemistry and electron microscopy | 262 | ||
| Large cell carcinoma with neuroendocrine morphology | 262 | ||
| Non–small cell carcinomas with neuroendocrine differentiation | 263 | ||
| Carcinoid Tumors | 263 | ||
| Pathologic features | 263 | ||
| Immunohistochemistry and electron microscopy | 263 | ||
| Tumorlets and Diffuse Idiopathic Pulmonary NE Cell Hyperplasia | 264 | ||
| Summary | 264 | ||
| References | 265 | ||
| Clinical Presentation and Evaluation of Neuroendocrine Tumors of the Lung | 267 | ||
| Key points | 267 | ||
| Introduction | 267 | ||
| Clinical presentation | 267 | ||
| Epidemiology | 267 | ||
| Symptoms | 268 | ||
| Endocrine Syndromes | 268 | ||
| Carcinoid tumors | 268 | ||
| SCLC or LCNEC | 268 | ||
| Radiographic presentation | 268 | ||
| Central Carcinoid Tumors | 268 | ||
| Peripheral Carcinoid Tumors | 269 | ||
| Metabolic Imaging for Carcinoid Tumors | 269 | ||
| SCLC | 269 | ||
| LCNEC | 269 | ||
| Clinical approach to patients | 270 | ||
| Central Carcinoid Tumors | 270 | ||
| Ectopic Cushing and Other Paraneoplastic Syndromes in Thoracic Neuroendocrine Tumors | 277 | ||
| Key points | 277 | ||
| Ectopic Cushing syndrome | 278 | ||
| Syndrome of inappropriate antidiuretic hormone secretion | 281 | ||
| Ectopic acromegaly | 281 | ||
| Carcinoid syndrome | 282 | ||
| Hyperparthyroidism linked to ectopic parathormone and parathormone-related peptide production | 282 | ||
| References | 282 | ||
| Functional Imaging Evaluation in the Detection, Diagnosis, and Histologic Differentiation of Pulmonary Neuroendocrine Tumors | 285 | ||
| Key points | 286 | ||
| Introduction | 286 | ||
| Role of the 18F FDG–PET-CT scan | 287 | ||
| Role of 68Ga DOTA-peptides PET-CT scan | 288 | ||
| Dual-tracer PET evaluation using 68Ga DOTA-peptides and 18F FDG | 289 | ||
| Other Tracers in PC Evaluation | 291 | ||
| References | 291 | ||
| The Significance of Histology | 293 | ||
| Key points | 293 | ||
| Spanish multicenter experience | 293 | ||
| What is the nodal involvement impact in these tumors? | 294 | ||
| When is a conservative resection of parenchyma in carcinoid tumors worthwhile? | 295 | ||
| Tumor Local Recurrence and Distant Metastasis Treatment and Prognosis | 296 | ||
| What Is the Real Frequency of Recurrence in Bronchial Carcinoids? Which Factors Influence Them? | 296 | ||
| How Should the Follow-Up Designed? | 296 | ||
| How to Treat Metastases? | 297 | ||
| Could We Consider as Useful the Design of New Diagnosis and Treatment Strategies in Carcinoid Pulmonary Tumors? | 297 | ||
| References | 297 | ||
| Bronchoplastic Procedures for Carcinoid Tumors | 299 | ||
| Key points | 299 | ||
| Surgical technique | 300 | ||
| Comment | 301 | ||
| References | 302 | ||
| Large-Cell Neuroendocrine Carcinoma of the Lung | 305 | ||
| Key points | 305 | ||
| Introduction | 305 | ||
| Clinical characteristics | 305 | ||
| Pathology | 306 | ||
| Survival | 307 | ||
| Treatment | 308 | ||
| Summary | 309 | ||
| References | 309 | ||
| Neuroendocrine Tumors of the Lung | 313 | ||
| Key points | 313 | ||
| Introduction | 313 | ||
| Rationale for surgery | 315 | ||
| Suspicious Pulmonary Lesions | 315 | ||
| Improved Local Control | 315 | ||
| Mixed Small Cell and Non–Small Cell Histology | 316 | ||
| Salvage Operation for Initial Failure or Relapse | 316 | ||
| Synchronous Ipsilateral or Bilateral Small and Non–Small Cell Tumors | 317 | ||
| Second Primary Lung Cancer | 317 | ||
| Preoperative evaluation | 317 | ||
| Treatment modalities including surgery | 318 | ||
| Surgery Alone | 318 | ||
| Surgery with Adjuvant CTx | 318 | ||
| Induction CTx Followed by Surgery | 319 | ||
| Induction Chemoradiotherapy Followed by Surgery | 321 | ||
| Summary | 321 | ||
| References | 322 | ||
| Thymic Neuroendocrine Tumors | 327 | ||
| Key points | 327 | ||
| Epidemiology | 327 | ||
| Classification | 327 | ||
| Clinical features | 327 | ||
| Histologic Features | 329 | ||
| Gross features | 330 | ||
| Immunohistochemistry | 330 | ||
| Electron microscopy | 330 | ||
| Treatment and outcome | 330 | ||
| Management of Localized Disease | 330 | ||
| Management of Advanced/Metastatic Disease | 330 | ||
| References | 331 | ||
| Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors | 333 | ||
| Key points | 333 | ||
| Introduction | 333 | ||
| Overview | 334 | ||
| Non-somatostatin-based therapies | 335 | ||
| Medical Therapy | 335 | ||
| Angiographic Liver-directed Techniques | 336 | ||
| Somatostatin analogue-related therapies | 337 | ||
| PRRT Background | 337 | ||
| PRRT Clinical Protocol | 338 | ||
| PRRT Technique | 339 | ||
| PRRT Efficacy | 339 | ||
| PRRT and Bronchopulmonary NETs | 339 | ||
| PRRT Safety Profile | 343 | ||
| Final considerations | 345 | ||
| References | 346 | ||
| Medical Treatment of Advanced Thoracic Neuroendocrine Tumors | 351 | ||
| Key points | 351 | ||
| Introduction | 351 | ||
| Control of associated neuroendocrine hypersecretions | 352 | ||
| Medical therapy for primary tumor in patients not candidates for surgery, in multicentric forms, and in patients with advan ... | 352 | ||
| SSA as antiproliferative agents | 353 | ||
| Target therapies | 353 | ||
| Chemotherapy | 353 | ||
| Summary | 354 | ||
| References | 354 | ||
| Index | 357 |